News Releases

Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients NDA was submitted in May 2019 ; product launch anticipated in 1H 2020 Lamotrigine market currently exceeds $700 million annually DEER PARK, Ill.

DEER PARK, Ill. , May 15, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen , Chief Executive Officer, will present at the 20 th Annual B.

– Four Products Currently Under Review with the FDA –  – Expecting Multiple Product Launches in Second Half of 2019 – – Company to Host Conference Call and Webcast today at 4:30 p.m. ET ( 3:30 p.m. CT ) - DEER PARK, Ill. , May 07, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc.

DEER PARK, Ill. , April 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2019 financial and operating results on Tuesday,

NDA filing for ET-202 Accepted for Review and Assigned PDUFA Date of October 21, 2019 DEER PARK, Ill. , March 25, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported

FDA Previously Granted DS-200 Fast Track Designation DEER PARK, Ill. , March 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for DS-200 via the

DEER PARK, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen , Chief Executive Officer, will participate in a fireside chat

If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind EM-100 Has Been Submitted to the FDA for Review LAVAL, Quebec and DEER PARK, Ill., Feb. 19, 2019 – Bausch Health Companies Inc. (NYSE/TSX: BHC) and Bausch + Lomb, its wholly owned subsidiary and a leading global eye

Transaction adds an additional potential 2019 product launch to Eton’s pipeline ET-202 NDA was submitted in December 2018 ; PDUFA date expected to be in Q4 2019 ET-203 NDA expected to be submitted by Q3 2019 DEER PARK, Ill. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc.

New Drug Application expected to be filed in 2019 DEER PARK, Ill. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into a